LY-294002, also known as 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, is a widely used inhibitor of the phosphoinositide 3-kinase (PI3K) signaling pathway. The chemical name of LY-294002 is 6-Chloro-2-methoxy-N-(2-morpholin-4-ylethyl)-9-phenyl-4H-benzo[b][1,4]oxazin-4-imine. The molecular formula of LY-294002 is C19H17ClN2O3 and its formula weight is 352.80. The CAS No of LY-294002 is 154447-36-6.
Top Ten Keywords and Synonyms:
Synonyms: 2-(4-Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one; 6-Chloro-2-methoxy-N-(2-morpholin-4-ylethyl)-9-phenyl-4H-benzo[b][1,4]oxazin-4-imine; LY294002; LY 294002.
Health Benefits of LY-294002:
LY-294002 has been found to exhibit potential health benefits in several preclinical studies, including:
Inhibiting tumor cell proliferation: LY-294002 has been shown to inhibit the proliferation of various cancer cells by blocking the PI3K/AKT signaling pathway, which plays a crucial role in cancer cell growth and survival.
Improving insulin sensitivity: Several studies have demonstrated that LY-294002 can improve insulin sensitivity and glucose uptake by inhibiting the PI3K/AKT signaling pathway.
Reducing inflammation: LY-294002 has been found to possess anti-inflammatory properties by inhibiting the activation of NF-κB, a transcription factor that plays a crucial role in the regulation of inflammation.
Potential Effects of LY-294002:
LY-294002 is a potent inhibitor of the PI3K/AKT signaling pathway, and thus it may exhibit potential effects in various disease conditions, such as cancer, inflammation, and metabolic disorders.
Cancer: PI3K signaling plays a crucial role in cancer cell proliferation, survival, and metastasis. Thus LY-294002, by blocking this signaling pathway, can potentially inhibit tumorigenesis.
Inflammation: The PI3K/AKT signaling pathway is known to regulate inflammation. LY-294002 can potentially inhibit the activation of NF-κB, a key regulator of inflammation, and thus reduce inflammation.
Metabolic disorders: The PI3K/AKT signaling pathway plays a critical role in the regulation of glucose uptake and metabolism. LY-294002, by inhibiting this pathway, can potentially improve insulin sensitivity and glucose uptake in metabolic disorders such as diabetes.
Product Mechanism:
LY-294002 is a potent inhibitor of the PI3K/AKT signaling pathway. PI3K is an enzyme that catalyzes the production of phosphatidylinositol-3,4,5-trisphosphate (PIP3), which activates AKT, a protein kinase that regulates various cellular processes, including proliferation, survival, and metabolism. LY-294002 inhibits the activity of PI3K, thereby blocking the production of PIP3 and the activation of AKT. This inhibition leads to reduced cell proliferation, survival, and metabolism, and thus it exhibits potential effects in various diseases.
Safety:
LY-294002 has been extensively studied in preclinical studies, and it has been found to be generally safe and well-tolerated. However, like any other drug, LY-294002 can cause side effects in some individuals.
Side Effects:
The most common side effects of LY-294002 reported in preclinical studies include:
Dosing Information:
The dosing information of LY-294002 varies depending on the specific preclinical study or application. However, the typical dose of LY-294002 ranges from 10 µM to 50 µM in in vitro studies, and from 10 mg/kg to 50 mg/kg in in vivo studies.
Conclusion:
LY-294002 is a potent inhibitor of the PI3K/AKT signaling pathway, and it exhibits potential effects in various disease conditions such as cancer, inflammation, and metabolic disorders. However, its safety and efficacy in clinical studies need to be further evaluated. Thus, LY-294002 holds great promise as a potential therapeutic agent for various diseases, but more research is needed to fully understand its mechanisms of action and clinical applications.
